The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells.

The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells.

A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence.

A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence.

An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 35 to 67; or (b) a polypeptide comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc.

An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 35 to 67; or (b) a polypeptide comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc.

A composition of drug targets and the use the method of using thereof. The composition comprises a vector and a drug using FKBP10 and PCOLCE genes and/or the encoded proteins thereof as drug targets.

The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.

The present invention provides: a method for identifying a blood cancer patient who may benefit from a monotherapy using a drug comprising a DNA methyl transferase inhibitor and a combination therapy using the aforesaid drug together with another epigenetic controller; a pharmaceutical composition to be used in treating a patient who has been identified or selected by the method; and a kit for identifying such a patient. More particularly, the aforesaid method comprises a step for measuring the expression amount of DUSP5 in a sample obtained from a blood cancer patient. When the expression amount measured in this step is lower than a reference expression amount of DUSP5, then the patient is identified or selected as a blood cancer patient who may benefit from a treatment using the drug comprising a DNA methyl transferase inhibitor.